Cargando…

PARP Inhibitors in Ovarian Cancer: A Review

Poly(ADP-ribose) polymerase (PARP) inhibitors (PARPis) have transformed the ovarian cancer (OC) treatment landscape. This narrative review provides a comprehensive overview of data for the PARPis olaparib, niraparib, and rucaparib in patients with OC and discusses their role in disease management, w...

Descripción completa

Detalles Bibliográficos
Autores principales:	O’Malley, David M., Krivak, Thomas C., Kabil, Nashwa, Munley, Jiefen, Moore, Kathleen N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2023
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10344972/ https://www.ncbi.nlm.nih.gov/pubmed/37268756 http://dx.doi.org/10.1007/s11523-023-00970-w

Ejemplares similares

Olaparib treatment for platinum-sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency status Phase II LIGHT study primary analysis
por: Cadoo, Karen, et al.
Publicado: (2022)

PARP Inhibitors in Breast and Ovarian Cancer
por: Wang, Samuel S. Y., et al.
Publicado: (2023)

PARP inhibitors in ovarian cancer
por: Cibula, David, et al.
Publicado: (2015)

PARP Inhibitors in Ovarian Cancer: The Route to “Ithaca”
por: Boussios, Stergios, et al.
Publicado: (2019)

Integration of PARP-inhibitors in ovarian cancer therapy
por: Pietragalla, Antonella, et al.
Publicado: (2020)

First-line PARP inhibitors in ovarian cancer: summary of an ESMO Open - Cancer Horizons round-table discussion
por: Banerjee, Susana, et al.
Publicado: (2020)

New treatment option for ovarian cancer: PARP inhibitors
por: Meehan, Robert S., et al.
Publicado: (2016)

Overcoming Platinum and PARP-Inhibitor Resistance in Ovarian Cancer
por: McMullen, Michelle, et al.
Publicado: (2020)

The role of PARP inhibitor combination therapy in ovarian cancer
por: Hockings, Helen, et al.
Publicado: (2023)

Rucaparib: the past, present, and future of a newly approved PARP inhibitor for ovarian cancer
por: Dockery, LE, et al.
Publicado: (2017)

PARP inhibitors in ovarian cancer: Sensitivity prediction and resistance mechanisms
por: Jiang, Xuan, et al.
Publicado: (2019)

Fighting resistance: post-PARP inhibitor treatment strategies in ovarian cancer
por: Veneziani, Ana C., et al.
Publicado: (2023)

The Emerging Role of PARP Inhibitors in the Treatment of Epithelial Ovarian Cancer
por: Gien, Lilian T., et al.
Publicado: (2010)

PARP inhibitors in ovarian cancer: overcoming resistance with combination strategies
por: Miller, Rowan E, et al.
Publicado: (2022)

Perspectives on PARP Inhibitor Combinations for Ovarian Cancer
por: Bonadio, Renata Colombo, et al.
Publicado: (2021)

Rucaparib: a novel PARP inhibitor for BRCA advanced ovarian cancer
por: Colombo, Ilaria, et al.
Publicado: (2018)

Recent Insights into PARP and Immuno-Checkpoint Inhibitors in Epithelial Ovarian Cancer
por: Revythis, Antonios, et al.
Publicado: (2022)

PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer
por: Morgan, Robert D., et al.
Publicado: (2018)

Ovarian Cancer Treatments Strategy: Focus on PARP Inhibitors and Immune Check Point Inhibitors
por: Nero, Camilla, et al.
Publicado: (2021)

Current status and future prospects of PARP inhibitor clinical trials in ovarian cancer
por: Jiang, Xuan, et al.
Publicado: (2019)

Overcoming PARP inhibitor resistance in ovarian cancer: what are the most promising strategies?
por: Klotz, Daniel Martin, et al.
Publicado: (2020)

Overcoming the challenges of drug development in platinum-resistant ovarian cancer
por: Eskander, Ramez N., et al.
Publicado: (2023)

Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models
por: Kim, Hyoung, et al.
Publicado: (2020)

HMGB3 promotes PARP inhibitor resistance through interacting with PARP1 in ovarian cancer
por: Ma, Hanlin, et al.
Publicado: (2022)

PARP inhibitors and epithelial ovarian cancer: Molecular mechanisms, clinical development and future prospective
por: Loizzi, Vera, et al.
Publicado: (2020)

Differences in PARP Inhibitors for the Treatment of Ovarian Cancer: Mechanisms of Action, Pharmacology, Safety, and Efficacy
por: Valabrega, Giorgio, et al.
Publicado: (2021)

Clinical Landscape of PARP Inhibitors in Ovarian Cancer: Molecular Mechanisms and Clues to Overcome Resistance
por: Kyo, Satoru, et al.
Publicado: (2022)

Clinical application of PARP inhibitors in ovarian cancer: from molecular mechanisms to the current status
por: Wu, Yongsong, et al.
Publicado: (2023)

Combined Strategies with Poly (ADP-Ribose) Polymerase (PARP) Inhibitors for the Treatment of Ovarian Cancer: A Literature Review
por: Boussios, Stergios, et al.
Publicado: (2019)

The Molecular Mechanisms of Actions, Effects, and Clinical Implications of PARP Inhibitors in Epithelial Ovarian Cancers: A Systematic Review
por: Lau, Chien-Hui, et al.
Publicado: (2022)

The development of PARP inhibitors in ovarian cancer: from bench to bedside
por: Drew, Yvette
Publicado: (2015)

Efficacy and Prognostic Factors for PARP Inhibitors in Patients With Ovarian Cancer
por: Huang, Xuan-zhang, et al.
Publicado: (2020)

Oxaliplatin prior to PARP inhibitor in BRCA-mutated ovarian cancer
por: Nicoletto, Maria Ornella, et al.
Publicado: (2023)

Combined treatment of disulfiram with PARP inhibitors suppresses ovarian cancer
por: Tang, Bin, et al.
Publicado: (2023)

An update on PARP inhibitors for the treatment of cancer
por: Benafif, Sarah, et al.
Publicado: (2015)

Advances in PARP Inhibitors for Prostate Cancer
por: Tisseverasinghe, Steven, et al.
Publicado: (2023)

An effective AKT inhibitor-PARP inhibitor combination therapy for recurrent ovarian cancer
por: Xu, Jing, et al.
Publicado: (2022)

Ovarian Cancer Therapy: Homologous Recombination Deficiency as a Predictive Biomarker of Response to PARP Inhibitors
por: Miller, Rowan E, et al.
Publicado: (2022)

PARP inhibitors in ovarian cancer: Clinical evidence for informed treatment decisions
por: Ledermann, Jonathan A, et al.
Publicado: (2015)

Overcoming resistance to PARP inhibitor in epithelial ovarian cancer, are we ready?
por: Ray-Coquard, Isabelle, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ppi5meeqjfbfv9qa9fj1tl8dqj